Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

Blood

Volumn 101, Issue 5, 2003, Pages 1692-1697

  Cortes, Jorge ^a   Albitar, Maher ^b   Thomas, Deborah ^b   Giles, Francis ^b   Kurzrock, Razelle ^b   Thibault, Alain ^b   Rackoff, Wayne ^b   Koller, Charles ^b   O'Brien, Susan ^b   Garcia Manero, Guillermo ^b   Talpaz, Moshe ^b   Kantarjian, Hagop ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; DEXAMETHASONE; DOXORUBICIN; IMATINIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; VASCULOTROPIN; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOGENETICS; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; FATIGUE; HUMAN; LEUKOCYTE COUNT; LEUKOCYTE DIFFERENTIAL COUNT; LIVER TOXICITY; MULTIPLE MYELOMA; MYELOFIBROSIS; NAUSEA; NEPHROTOXICITY; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; SIDE EFFECT; SPLENOMEGALY; TREATMENT OUTCOME; VOMITING;

EID: 0037372488     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-07-1973     Document Type: Article

References (38)

1. Rebollo A, Martinez AC. Ras proteins: recent advances and new functions. Blood. 1999;94:2971-2980.
2. Beaupre DM, Kurzrock R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol. 1999;17:1071-1079.
3. Khosravi-Far R, Cox AD, Kato K, Der CJ. Protein prenylation: key to ras function and cancer intervention? Cell Growth Differ. 1992;3:461-469.
4. Gelb MH. Protein prenylation, et cetera: signal transduction in two dimensions. Science. 1997;275:1750-1751
5. Rodenhuls S. ras and human tumors. Semin Cancer Biol. 1992;3:241-247.
6. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
7. Pull L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 1994;13:764-773.
8. Faded S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164-172.
9. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 2001;93:1062-1074.
10. End DW. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest New Drugs. 1999;17:241-258.
11. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransterase: A strategic target for anticancer therapeutic development. J Clin Oncol. 1999;17:3631-3652.
12. Prendergast GC, Oliff A. Farnesyltransterase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects. Semin Cancer Biol. 2000;10:443-452.
13. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001;61:131-137.
14. Aguayo A, Kantarjian H, Manshouri T et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240-2245.
15. Verstovsek S, Kantarjian H, Manshouri T, et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood. 2002;99:2265-2267.
16. Zhang B, Prendergast GC, Fenton RG. Farnesyl-transferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res. 2002;62:450-458.
17. Kartarjlan HM, Smith T, O'Brien S, Beran M, Pierce S, Talpaz M, The Leukemia Service. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med. 1995;122:254-261.
18. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361-3369.
19. Kurzrock R, Cortes JE, Ryback ME, et al. Phase II study of R115777, a farnesyltransferase inhibitor, in myelodysplastic syndrome. Blood. 2001;98:848a.
20. Kurzrock R, Sebti SM, Kantarjian HM, et al. Phase I study of a farnesyl transferase inhibitor, R115777, in patients with myelodysplastic syndrome. Blood. 2001;98:623a.
21. Peters DG, Hoover RR, Gerlach MJ, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001;97:1404-1412.
22. Reichert A, Helsterkamp N, Daley GQ, Groffen J. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the famesyl transferase inhibitor SCH66336. Blood. 2001;97:1399-1403.
23. Hoover RR, Mahon F-X, Melo JV, Daley GQ. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 2002;100:1068-1071.
24. Nakajima A, Tauchi T, Sumi M, Bishop WR, Ohyashiki K. Efficacy of SCH66336, the farnesyl transferase inhibitor, in conjunction with other antileukemic agents against Glivec-resistant BCR-ABL-positive cells. Blood. 2001;98:575a.
25. Mesa RA, Tefferi A, Gray L, Schroeder G, Kaufmann SH. The farnesyltransferase inhibitor, R115777, has significant in vitro activity in myelofibrosis with myeloid metaplasia. Blood. 2001;98:469a.
26. Bolick SC, Sebti SM, Hamilton TH, Landowski TH, Dalton WS. Activity of farnesyl transferase inhibitor, FTI-277, in human myeloma cells correlates with inhibition of Ras processing. Clin Cancer Res. 2001;7:3805s
27. Beaupre DM, Grad J, Bahlis N, Boise LH, Lichtenheld MG. Preclinical investigation of a farnesyl transferase inhibitor for multiple myeloma. Blood. 2001;98:640a.
28. Alsina M, Overton R, Belle N, et al. Farnesyl transferase inhibitor FTI-R115777 is well tolerated, induces stabilization of disease and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Proceedings of AACR. 2002;43:1000 (Abstract no. 4960).
29. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood. 2000;96:1655-1669.
30. Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol. 1999;19:1831-1840.
31. Ashar HR, James L, Gray K, et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem. 2000;275:30451-30457.
32. Lobell RB, Omer CA, Abrams MT, et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 2001;61:8758-8768.
33. Tahir SK, Gu WZ, Zhang HC, et al. Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue. Eur J Cancer. 2000;36:1161-1170.
34. Gu WZ, Tahir SK, Wang YC, Zhang HC, Cherian SP, O'Connor S, Leal JA, Rosenberg SH, Ng SC. Effect of novel CAAX peptidomimetic farnesyl-transferase inhibitor on angiogenesis in vitro and in vivo. Eur J Cancer. 1999;35:1394-1401.
35. Feldkamp MM, Lau N, Guha A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene. 1999;18:7514-7526.
36. Charvat S, Duchesne M, Parvaz P, Chignol MC, Schmitt D, Serres M. The up-regulation of vascular endothelial growth factor in mutated Ha-ras HaCaT cell lines is reduced by a farnesyl transferase inhibitor. Anticancer Res. 1999;19:557-561.
37. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995;55:4575-4580.
38. Feldkamp MM, Lau N, Rak J, Kerbel RS, Guha A. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int J Cancer. 1999;81:118-124.